CoChat
Sign Up
Cited by 52Autism Spectrum Disorder ResearchLipid Membrane Structure and BehaviorGenetics and Neurodevelopmental Disorders

Lipid rafts: A signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders

Open access
Wang, Hansen·2014·Frontiers in Behavioral Neuroscience
DOI 10.3389/fnbeh.2014.00104PMC PMC3973904
Open this paper in CoChat — free accountOpen PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnbeh.2014.00104

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 62 · Cited by 52

Research works printed but not linked: 50

  1. Allen J. A. Halverson-Tamboli R. A. Rasenick M. M. (2007). Lipid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci. 8, 128– 140 10.1038/nrn2059 17195035 · DOI
  2. Auerbach B. D. Osterweil E. K. Bear M. F. (2011). Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63– 68 10.1038/nature10658 22113615 PMC3228874 · DOI · Paper page
  3. Baker S. A. Chen L. Wilkins A. D. Yu P. Lichtarge O. Zoghbi H. Y. (2013). An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 152, 984– 996 10.1016/j.cell.2013.01.038 23452848 PMC3641682 · DOI · Paper page
  4. Bukelis I. Porter F. D. Zimmerman A. W. Tierney E. (2007). Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am. J. Psychiatry 164, 1655– 1661 10.1176/appi.ajp.2007.07020315 17974928 · DOI
  5. Delint-Ramirez I. Fernandez E. Bayes A. Kicsi E. Komiyama N. H. Grant S. G. (2010). In vivo composition of NMDA receptor signaling complexes differs between membrane subdomains and is modulated by PSD-95 and PSD-93. J. Neurosci. 30, 8162– 8170 10.1523/JNEUROSCI.1792-10.2010 20554866 PMC2912510 · DOI
  6. Delorme R. Ey E. Toro R. Leboyer M. Gillberg C. Bourgeron T. (2013). Progress toward treatments for synaptic defects in autism. Nat. Med. 19, 685– 694 10.1038/nm.3193 23744158 · DOI · Paper page
  7. Diaz-Stransky A. Tierney E. (2012). Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 160C, 295– 300 10.1002/ajmg.c.31342 23042585 · DOI
  8. Dziobek I. Gold S. M. Wolf O. T. Convit A. (2007). Hypercholesterolemia in Asperger syndrome: independence from lifestyle, obsessive-compulsive behavior, and social anxiety. Psychiatry Res. 149, 321– 324 10.1016/j.psychres.2006.02.003 17123635 · DOI · Paper page
  9. Ebert D. H. Greenberg M. E. (2013). Activity-dependent neuronal signalling and autism spectrum disorder. Nature 493, 327– 337 10.1038/nature11860 23325215 PMC3576027 · DOI · Paper page
  10. Fielding C. J. Fielding P. E. (2004). Membrane cholesterol and the regulation of signal transduction. Biochem. Soc. Trans. 32, 65– 69 10.1042/BST0320065 14748714 · DOI
  11. Francesconi A. Kumari R. Zukin R. S. (2009). Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar/lipid raft pathway. J. Neurosci. 29, 3590– 3602 10.1523/JNEUROSCI.5824-08.2009 19295163 PMC2734995 · DOI
  12. Hering H. Lin C. C. Sheng M. (2003). Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 23, 3262– 3271 12716933 PMC6742299
  13. Huguet G. Ey E. Bourgeron T. (2013). The genetic landscapes of autism spectrum disorders. Annu. Rev. Genomics Hum. Genet. 14, 191– 213 10.1146/annurev-genom-091212-153431 23875794 · DOI
  14. Karasinska J. M. Hayden M. R. (2011). Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 7, 561– 572 10.1038/nrneurol.2011.132 21894212 · DOI · Paper page
  15. Korade Z. Kenworthy A. K. (2008). Lipid rafts, cholesterol, and the brain. Neuropharmacology 55, 1265– 1273 10.1016/j.neuropharm.2008.02.019 18402986 PMC2638588 · DOI · Paper page
  16. Krumm N. O'Roak B. J. Shendure J. Eichler E. E. (2014). A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 37, 95– 105 10.1016/j.tins.2013.11.005 24387789 PMC4077788 · DOI · Paper page
  17. Kumari R. Castillo C. Francesconi A. (2013). Agonist-dependent signaling by group I metabotropic glutamate receptors is regulated by association with lipid domains. J. Biol. Chem. 288, 32004– 32019 10.1074/jbc.M113.475863 24045944 PMC3814796 · DOI
  18. Lee R. W. Tierney E. (2011). Hypothesis: the role of sterols in autism spectrum disorder. Autism Res. Treat. 2011: 653570 10.1155/2011/653570 22937253 PMC3420784 · DOI · Paper page
  19. Levitan I. Fang Y. Rosenhouse-Dantsker A. Romanenko V. (2010). Cholesterol and ion channels. Subcell. Biochem. 51, 509– 549 10.1007/978-90-481-8622-8_19 20213557 PMC2895485 · DOI · Paper page
  20. Li W. Cui Y. Kushner S. A. Brown R. A. Jentsch J. D. Frankland P. W. (2005). The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 15, 1961– 1967 10.1016/j.cub.2005.09.043 16271875 · DOI
  21. Lingwood D. Simons K. (2010). Lipid rafts as a membrane-organizing principle. Science 327, 46– 50 10.1126/science.1174621 20044567 · DOI · Paper page
  22. Liu Q. Yao W. D. Suzuki T. (2013). Specific interaction of postsynaptic densities with membrane rafts isolated from synaptic plasma membranes. J. Neurogenet. 27, 43– 58 10.3109/01677063.2013.772175 23527882 · DOI
  23. Lyst M. J. Ekiert R. Ebert D. H. Merusi C. Nowak J. Selfridge J. (2013). Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16, 898– 902 10.1038/nn.3434 23770565 PMC3786392 · DOI · Paper page
  24. Mauch D. H. Nagler K. Schumacher S. Goritz C. Muller E. C. Otto A. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354– 1357 10.1126/science.294.5545.1354 11701931 · DOI · Paper page
  25. Murdoch J. D. State M. W. (2013). Recent developments in the genetics of autism spectrum disorders. Curr. Opin. Genet. Dev. 23, 310– 315 10.1016/j.gde.2013.02.003 23537858 · DOI
  26. Nagy G. Ackerman S. L. (2013). Cholesterol metabolism and Rett syndrome pathogenesis. Nat. Genet. 45, 965– 967 10.1038/ng.2738 23985682 · DOI · Paper page
  27. Pani A. Mandas A. Dessi S. (2010). Cholesterol, Alzheimer's disease, prion disorders: a menage a trois? Curr. Drug Targets 11, 1018– 1031 10.2174/138945010791591386 20450474 · DOI
  28. Persico A. M. Napolioni V. (2013). Autism genetics. Behav. Brain Res. 251, 95– 112 10.1016/j.bbr.2013.06.012 23769996 · DOI
  29. Pfrieger F. W. (2003). Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60, 1158– 1171 10.1007/s00018-003-3018-7 12861382 PMC11138592 · DOI · Paper page
  30. Pristera A. Okuse K. (2011). Building excitable membranes: lipid rafts and multiple controls on trafficking of electrogenic molecules. Neuroscientist 18, 70– 81 10.1177/1073858410393977 21518816 · DOI
  31. Santoro M. R. Bray S. M. Warren S. T. (2012). Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7, 219– 245 10.1146/annurev-pathol-011811-132457 22017584 · DOI · Paper page
  32. Schmunk G. Gargus J. J. (2013). Channelopathy pathogenesis in autism spectrum disorders. Front. Genet. 4: 222 10.3389/fgene.2013.00222 24204377 PMC3817418 · DOI
  33. Sebastiao A. M. Colino-Oliveira M. Assaife-Lopes N. Dias R. B. Ribeiro J. A. (2012). Lipid rafts, synaptic transmission and plasticity: impact in age-related neurodegenerative diseases. Neuropharmacology 64, 97– 107 10.1016/j.neuropharm.2012.06.053 22820274 · DOI
  34. Sheng M. Kim E. (2011). The postsynaptic organization of synapses. Cold Spring Harb. Perspect. Biol. 3: a005678 10.1101/cshperspect.a005678 22046028 PMC3225953 · DOI · Paper page
  35. Simons K. Ehehalt R. (2002). Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110, 597– 603 10.1172/JCI0216390 12208858 PMC151114 · DOI
  36. Simons K. Sampaio J. L. (2011). Membrane organization and lipid rafts. Cold Spring Harb. Perspect. Biol. 3: a004697 10.1101/cshperspect.a004697 21628426 PMC3179338 · DOI
  37. Simons K. Toomre D. (2000). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31– 39 10.1038/35036052 11413487 · DOI
  38. Suzuki T. Zhang J. Miyazawa S. Liu Q. Farzan M. R. Yao W. D. (2011). Association of membrane rafts and postsynaptic density: proteomics, biochemical, and ultrastructural analyses. J. Neurochem. 119, 64– 77 10.1111/j.1471-4159.2011.07404.x 21797867 PMC3184177 · DOI
  39. Tsui-Pierchala B. A. Encinas M. Milbrandt J. Johnson E. M. Jr. (2002). Lipid rafts in neuronal signaling and function. Trends Neurosci. 25, 412– 417 10.1016/S0166-2236(02)02215-4 12127758 · DOI
  40. van der Most P. J. Dolga A. M. Nijholt I. M. Luiten P. G. Eisel U. L. (2009). Statins: mechanisms of neuroprotection. Prog. Neurobiol. 88, 64– 75 10.1016/j.pneurobio.2009.02.002 19428962 · DOI · Paper page
  41. Waage-Baudet H. Dunty W. C. Jr. Dehart D. B. Hiller S. Sulik K. K. (2005). Immunohistochemical and microarray analyses of a mouse model for the smith-lemli-opitz syndrome. Dev. Neurosci. 27, 378– 396 10.1159/000088453 16280635 · DOI
  42. Wang H. Doering L. C. (2013). Reversing autism by targeting downstream mTOR signaling. Front. Cell. Neurosci. 7: 28 10.3389/fncel.2013.00028 23533374 PMC3607786 · DOI
  43. Wang H. Kim S. S. Zhuo M. (2010). Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. J. Biol. Chem. 285, 21888– 21901 10.1074/jbc.M110.116293 20457613 PMC2898437 · DOI · Paper page
  44. Wang H. Wu L. J. Kim S. S. Lee F. J. Gong B. Toyoda H. (2008b). FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 59, 634– 647 10.1016/j.neuron.2008.06.027 18760699 · DOI · Paper page
  45. Wang H. Wu L. J. Zhang F. Zhuo M. (2008a). Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. J. Neurosci. 28, 4385– 4397 10.1523/JNEUROSCI.0646-08.2008 18434517 PMC6670940 · DOI
  46. Wang H. Zhuo M. (2012). Group I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases. Front. Pharmacol. 3: 189 10.3389/fphar.2012.00189 23125836 PMC3485740 · DOI
  47. Wassif C. A. Zhu P. Kratz L. Krakowiak P. A. Battaile K. P. Weight F. F. (2001). Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith–Lemli–Opitz syndrome. Hum. Mol. Genet. 10, 555– 564 10.1093/hmg/10.6.555 11230174 · DOI · Paper page
  48. Won H. Mah W. Kim E. (2013). Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses. Front. Mol. Neurosci. 6: 19 10.3389/fnmol.2013.00019 23935565 PMC3733014 · DOI
  49. Xu X. Pozzo-Miller L. (2013). A novel DNA-binding feature of MeCP2 contributes to Rett syndrome. Front. Cell. Neurosci. 7: 64 10.3389/fncel.2013.00064 23675316 PMC3648697 · DOI
  50. Yaqoob P. Shaikh S. R. (2010). The nutritional and clinical significance of lipid rafts. Curr. Opin. Clin. Nutr. Metab. Care 13, 156– 166 10.1097/MCO.0b013e328335725b 20010096 · DOI

Authors
Wang, H.
Affiliations
University of Toronto (CA)
Corresponding author
Wang, Hansen
ORCID
Wang, Hansen
Venue
Frontiers in Behavioral Neuroscience
Publisher
Frontiers Media SA
Published
2014-03-27
Volume
8
Pages
104-104
ISSN
1662-5153 (ISSN-L)
DOI
10.3389/fnbeh.2014.00104
PMC
PMC3973904
OpenAlex
W1986327738
Cited by
52
References
62
Citations by year
2026: 4 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 8 · 2014: 1
FWCI
2.98
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Behavioral Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (30200152)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Lipid Membrane Structure and Behavior
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
lipid rafts, cholesterol metabolism, autism spectrum disorder, synaptic dysfunction, signaling platforms, membrane cholesterol

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review